An article in Benzinga highlights Syqe® Medical’s innovative SyqeAir Inhaler, emphasizing its role in addressing the global challenge of cannabis overdose through metered dosing. CEO of SyqeAir, Hagit Kamin, discusses how the Inhaler and Cartridges allow patients to achieve fast relief in the intensity of chronic neuropathic pain and PTSD symptoms without the risk of overdose. The article underscores Syqe®’s commitment to a safer yet equally effective medical cannabis treatment and marks another prestigious acknowledgment for the company. Read the full article>>

The Pharmacokinetics, Efficacy, Safety, and Ease of Use of the SyqeAir Metered-Dose Cannabis Inhaler for Chronic Neuropathic Pain: A Phase 1a Study
Syqe®’s first study examined whether metered and low doses of Δ9-THC allow for dose-dependent pain reduction of chronic neuropathic pain without significant adverse events. Listen to the podcast>>